Alliance Imaging CEO Richard Zehner is looking for acquisitionsto buttress the Orange, CA, company's claim that it is the nation'slargest mobile MRI and CT fleet. Alliance announced record third-quarter earnings and strong revenueresults on Oct. 17,
Alliance Imaging CEO Richard Zehner is looking for acquisitionsto buttress the Orange, CA, company's claim that it is the nation'slargest mobile MRI and CT fleet.
Alliance announced record third-quarter earnings and strong revenueresults on Oct. 17, five days after revealing that it had takendelivery of a GE 1-tesla Signa MRI to be deployed on a new routein Missouri.
For the third quarter (end-September), Alliance reported netincome of $1.4 million on revenues of $15.1 million. For the firstnine months of 1995, Alliance earned $3.6 million on revenuesof $44.3 million.
In the third quarter of last year, the company had a net lossof $1.4 million on revenues of $14.2 million. For the first ninemonths of 1994, it posted a net loss of $3.5 million on revenuesof $42.9 million.
Alliance also ended the period with a cash balance of over $10million, which in part is earmarked to buy competing mobile companies,according to Zehner.
"We're actively seeking and evaluating corporate acquisitionsto generate higher profitability and revenues from greater marketshare," he said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.